Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of ivonescimab plus platinum chemotherapy after EGFR-TKI failure in EGFR-mutant advanced non-squamous NSCLC
ChiCTR2500096483Phase 4Recruiting
- Sponsor
- University Town Hospital of Guangdong Provincial Hospital of Chinese Medicine
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by University Town Hospital of Guangdong Provincial Hospital of Chinese Medicine. Primary endpoint: Progression-free survival. Started Jan 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500096483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096483.